When was Exsilio founded?

Exsilio was founded in 2022 and raised its 1st funding round 1 year after it was founded.

Where is Exsilio located?

Exsilio is headquartered in Boston, United States.

Is Exsilio a funded company?

Exsilio is a funded company, having raised a total of $82M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2023.

When was the latest funding round of Exsilio?

Exsilio's latest funding was a $***** Series A round on Apr 08, 2024, with participation from 9 investors. Its primary sector is Gene Therapy. In United States, the Gene Therapy sector has seen $1.01B in funding in 2026 to date.

Where does Exsilio rank among its competitors?

Exsilio ranks 1269th amongst 3651 active competitors, of which 1233 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Exsilio?

Exsilio's top competitors include Jazz Pharmaceuticals, BeiGene and Alnylam. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Exsilio - 2026 Company Profile, Funding & Competitors

Exsilio is a series A company based in Boston (United States), founded in 2022. It operates as a Developer of genomic medicines for a broad range of diseases. Exsilio has raised $82M in funding from investors like Orbimed, Delos Capital and Novartis Venture Fund. The company has 3651 active competitors, including 1233 funded and 872 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Alnylam.

Company Details

Developer of genomic medicines for a broad range of diseases. The company is developing genomic medicines that can be delivered in lipid nanoparticles to treat a broad range of diseases, including genetic diseases, cancer, and autoimmune conditions. The company's technology is based on occurring genetic elements that can precisely insert new genes into a cell through RNA intermediate templates.

Website: exsiliotx.com
Email ID: *****@exsiliotx.com

Key Metrics

Founded Year

2022

Location

Boston, United States

Stage

Series A

Total Funding

$82M in 2 rounds

Latest Funding Round

Series A, Apr 08, 2024, $*****

Investors

Orbimed & 9 more

Ranked

1269^th among 3651 active competitors

Similar Companies

Jazz Pharmaceuticals & 3451 more

View Exsilio's full profile

Exsilio has raised a total funding of $82M over 2 rounds. Its first funding round was on 2023. Its latest funding round was a Series A round on Apr 08, 2024 for $*****. 9 investors participated in its latest round. Exsilio has 10 institutional investors.

Here is the list of recent funding rounds of Exsilio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 08, 2024	1664620	Series A	2786512	7298020	7769426	3303800
2023	3684	Seed	7666	7509	Orbimed	1268

Access funding benchmarks and valuations. Sign up today!

View details of Exsilio's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Exsilio include Jazz Pharmaceuticals, BeiGene and Alnylam. Here is the list of Top 10 competitors of Exsilio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	80/100
3rd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
4th	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
5th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
6th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 18 others	73/100
7th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
8th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
9th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
10th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
1269th	Exsilio 2022, Boston (United States), Series A	Developer of genomic medicines for a broad range of diseases	$82M	Invus, Orbimed & 8 others	39/100